Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹13 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹0 Cr
ROE
4.2 %
ROCE
12.6 %
P/E Ratio
39.5
P/B Ratio
1.6
Industry P/E
26.78
EV/EBITDA
6.9
Div. Yield
0 %
Debt to Equity
0
Book Value
₹16.2
EPS
₹0.7
Face value
10
Shares outstanding
4,996,100
CFO
₹7.33 Cr
EBITDA
₹-3.98 Cr
Net Profit
₹6.41 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Emmessar Biotech
| -11.1 | 5.2 | -11.1 | -22.4 | 0.2 | 11.4 | 10.5 |
|
BSE Healthcare
| -4.1 | -4.4 | -6.6 | 2.7 | 23.3 | 13.7 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Emmessar Biotech
| -34.2 | 66.1 | -0.9 | -10.3 | 43.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Emmessar Biotech
|
26.1 | 13.1 | 0.4 | 0.3 | -377.0 | 4.2 | 39.5 | 1.6 |
| 2,718.4 | 34,163.0 | 5,201.6 | 1,014.6 | 22.9 | 25 | 33.7 | 7.4 | |
| 7,806.0 | 19,457.5 | 2,177.5 | 200.9 | 11.3 | 26.5 | 96.9 | 23.4 | |
| 1,614.5 | 12,069.9 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.7 | 3.6 | |
| 1,316.6 | 18,343.8 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.5 | 5.1 | |
| 1,963.6 | 31,681.4 | 4,193.0 | 753.8 | 22.7 | 20.8 | 42 | 7.9 | |
| 4,770.9 | 21,985.9 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 4,825.9 | 8,013.6 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.3 | 11.5 | |
| 395.5 | 7,661.9 | 1,432.0 | 149.0 | 19.1 | 7.9 | 51.1 | 3.1 | |
| 989.2 | 9,195.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 18 | 3.1 |
No Review & Analysis are available.
Emmessar Biotech & Nutrition Limited, a healthcare company, manufactures and markets healthcare and nutritional products in India and internationally. It operates through Healthcare, Fine Chemicals, and Rent on Lease Land segments. The company offers... bone care, general health, muscle care, pain relief, sexual health, skin care, and skin cure products. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was founded in 1992 and is headquartered in Mumbai, India. Read more
Incorporated
1992
Chairman
--
Managing Director
Srinivasa Raghavan Mathurakavi Ayyangar
Headquarters
Raigad Dist, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsResults- Financial For 31-12-2025
11-Feb-2026Results For Quarter Ended September 30 2025
12-Nov-2025
The share price of Emmessar Biotech & Nutrition Ltd is ₹26.09 (BSE) as of 07-Apr-2026 13:40 IST. Emmessar Biotech & Nutrition Ltd has given a return of 0.19% in the last 3 years.
The P/E ratio of Emmessar Biotech & Nutrition Ltd is 39.49 times as on 07-Apr-2026, a 47 premium to its peers’ median range of 26.78 times.
The P/B ratio of Emmessar Biotech & Nutrition Ltd is 1.62 times as on 07-Apr-2026, a 64 discount to its peers’ median range of 4.47 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
48.02
|
1.97
|
|
2024
|
19.81
|
2.01
|
|
2023
|
24.59
|
1.86
|
|
2022
|
28.90
|
2.23
|
|
2021
|
5.07
|
1.29
|
The 52-week high and low of Emmessar Biotech & Nutrition Ltd are Rs 42.90 and Rs 18.42 as of 07-Apr-2026.
Emmessar Biotech & Nutrition Ltd has a market capitalisation of ₹ 13 Cr as on 07-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Emmessar Biotech & Nutrition Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹1.13
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.